| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/378745 |
| P8608 | Fatcat ID | release_3eqztje7gngtdn43fl35djitvm |
| P698 | PubMed publication ID | 14557960 |
| P5875 | ResearchGate publication ID | 9051941 |
| P50 | author | Loreen Herwaldt | Q57694571 |
| Michael A. Pfaller | Q62070176 | ||
| Shawn A Messer | Q62611307 | ||
| Daniel J. Diekema | Q43292463 | ||
| P2093 | author name string | Jianfang Hu | |
| Jeff Vande Berg | |||
| Kathleen Lee | |||
| Olafur Gudlaugsson | |||
| Shane Gillespie | |||
| P2860 | cites work | Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. | Q50700185 |
| Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. | Q54171057 | ||
| The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. | Q54568232 | ||
| A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients | Q28189320 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System | Q30585041 | ||
| Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America | Q33894467 | ||
| Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. | Q34085884 | ||
| Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility | Q34202154 | ||
| Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model | Q34429919 | ||
| Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality | Q35811186 | ||
| Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit | Q39596967 | ||
| Hospital-acquired fungemia. Its natural course and clinical significance | Q41074494 | ||
| Impact of nosocomial infections on outcome: myths and evidence | Q44039537 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| Nosocomial bloodstream infections in United States hospitals: a three-year analysis | Q44863798 | ||
| Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality | Q45101827 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | candidemia | Q54946225 |
| P304 | page(s) | 1172-1177 | |
| P577 | publication date | 2003-10-08 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Attributable mortality of nosocomial candidemia, revisited | |
| P478 | volume | 37 |
| Q92688020 | "Candida Albicans Interactions With The Host: Crossing The Intestinal Epithelial Barrier" |
| Q97644483 | 11g, a Potent Antifungal Candidate, Enhances Candida albicans Immunogenicity by Unmasking β-Glucan in Fungal Cell Wall |
| Q46172217 | 49th ICAAC annual meeting: optimization of anti-infective use in the clinical setting |
| Q35874892 | A Novel Small Molecule Inhibitor of Candida albicans Biofilm Formation, Filamentation and Virulence with Low Potential for the Development of Resistance |
| Q37012419 | A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients. |
| Q92662605 | A Re-Evaluation of the Relationship between Morphology and Pathogenicity in Candida Species |
| Q38261651 | A case of pediatric acute lymphoblastic leukemia with invasive candidiasis: short review. |
| Q33294780 | A cluster of Candida krusei infections in a haematological unit |
| Q36826923 | A competitive infection model of hematogenously disseminated candidiasis in mice redefines the role of Candida albicans IRS4 in pathogenesis |
| Q33378325 | A first Portuguese epidemiological survey of fungaemia in a university hospital |
| Q28539165 | A new tool to quantify receptor recruitment to cell contact sites during host-pathogen interaction |
| Q40429814 | A phagocytic cell line markedly improves survival of infected neutropenic mice |
| Q64123128 | A phenotypic small-molecule screen identifies halogenated salicylanilides as inhibitors of fungal morphogenesis, biofilm formation and host cell invasion |
| Q33709290 | A pre-therapeutic coating for medical devices that prevents the attachment of Candida albicans. |
| Q44104239 | A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia |
| Q31140994 | A quick and low-cost PCR-based assay for Candida spp. identification in positive blood culture bottles. |
| Q51187404 | A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. |
| Q34539213 | A risk factor analysis of healthcare-associated fungal infections in an intensive care unit: a retrospective cohort study |
| Q34669591 | A small molecule inhibitor of fungal histone acetyltransferase Rtt109. |
| Q35127891 | A small subpopulation of blastospores in candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and beta-1,6-glucan pathway genes |
| Q43648622 | A β-mannan trisaccharide conjugate vaccine aids clearance of Candida albicans in immunocompromised rabbits |
| Q33816237 | Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases |
| Q28744094 | Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis |
| Q35792197 | Active surveillance for candidemia, Australia |
| Q42104395 | Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. |
| Q58701180 | Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories |
| Q28830609 | Activity of crude extracts from Brazilian cerrado plants against clinically relevant Candida species |
| Q37918556 | Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations |
| Q79300225 | Adjunctive immunotherapy in combination with lipid-associated amphotericin B for the treatment of invasive candidiasis |
| Q36259905 | Advances and challenges in management of invasive mycoses |
| Q38082740 | Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections |
| Q38879361 | Alarmin(g) the innate immune system to invasive fungal infections |
| Q26830053 | All you need is light: antimicrobial photoinactivation as an evolving and emerging discovery strategy against infectious disease |
| Q39011788 | An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model |
| Q42589782 | An Interspecies Regulatory Network Inferred from Simultaneous RNA-seq of Candida albicans Invading Innate Immune Cells |
| Q41855352 | An Outbreak of Neonatal Candidemia Due to Non-albicans Candida Species in a Resource Constrained Setting of Uttarakhand State, India |
| Q34725594 | An integrated model of the recognition of Candida albicans by the innate immune system. |
| Q89284760 | Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship |
| Q37544444 | Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility |
| Q43449387 | Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin |
| Q59133696 | Anti-Candidal Activity and In Vitro Cytotoxicity Assessment of Graphene Nanoplatelets Decorated with Zinc Oxide Nanorods |
| Q36994288 | Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan. |
| Q37232404 | Antifungal Susceptibility Patterns of Candida Species Recovered from Endotracheal Tube in an Intensive Care Unit |
| Q39252456 | Antifungal activity of the ethanolic extracts of Punica granatum L. and evaluation of the morphological and structural modifications of its compounds upon the cells of Candida spp |
| Q34400255 | Antifungal clinical trials and guidelines: what we know and do not know |
| Q38840577 | Antifungal mechanism of [RuIII(NH3)4catechol]+ complex on fluconazole-resistant Candida tropicalis. |
| Q44402921 | Antifungal susceptibility testing of micafungin against Candida glabrata isolates |
| Q37322823 | Antimicrobial effect of para-alkoxyphenylcarbamic acid esters containing substituted N-phenylpiperazine moiety |
| Q28554670 | Antioxidant, Antimicrobial and Cytotoxic Properties as Well as the Phenolic Content of the Extract from Hancornia speciosa Gomes |
| Q36334389 | Antiproliferative effect and characterization of a novel antifungal peptide derived from human Chromogranin A. |
| Q37936568 | Apoptosis-inducing antifungal peptides and proteins. |
| Q54213135 | Appropriate Duration of Intravenous Treatment of Candidemia and Timing of Step Down to Oral Therapy in Non-neutropenic Patients. |
| Q35947401 | Assessment of Candida glabrata strain relatedness by pulsed-field gel electrophoresis and multilocus sequence typing |
| Q36633724 | Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis |
| Q27023720 | Association of genotypes with infection types and antifungal susceptibilities in Candida albicans as revealed by recent molecular typing strategies |
| Q38207033 | Attenuation of Candida albicans virulence with focus on disruption of its vacuole functions |
| Q36506378 | Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies |
| Q34999856 | Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia |
| Q36641985 | Bench-to-bedside review: Candida infections in the intensive care unit |
| Q36787173 | Bench-to-bedside review: sepsis, severe sepsis and septic shock - does the nature of the infecting organism matter? |
| Q21194915 | Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit |
| Q37392907 | Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates |
| Q37274233 | Biofilm formation in clinical Candida isolates and its association with virulence |
| Q35913891 | Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia |
| Q44913001 | Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies |
| Q34237335 | Canadian clinical practice guidelines for invasive candidiasis in adults |
| Q92592097 | Candida Bloodstream Infection: Changing Pattern of Occurrence and Antifungal Susceptibility over 10 Years in a Tertiary Care Saudi Hospital |
| Q35667405 | Candida albicans Cas5, a regulator of cell wall integrity, is required for virulence in murine and toll mutant fly models. |
| Q40162860 | Candida albicans Yeast, Pseudohyphal, and Hyphal Morphogenesis Differentially Affects Immune Recognition |
| Q34343343 | Candida albicans escapes from mouse neutrophils |
| Q36757536 | Candida albicans flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity |
| Q37410095 | Candida albicans hyphal formation and virulence assessed using a Caenorhabditis elegans infection model |
| Q27349803 | Candida albicans infection of Caenorhabditis elegans induces antifungal immune defenses |
| Q37204620 | Candida albicans triggers the expression of inflammatory genes in human umbilical vein endothelial cells |
| Q37345802 | Candida albicans-macrophage interactions: genomic and proteomic insights |
| Q36900101 | Candida albicans: A Model Organism for Studying Fungal Pathogens. |
| Q59282466 | Candida albicans: Clinical Relevance, Pathogenesis, and Host Immunity |
| Q37162081 | Candida albicans: genotyping methods and clade related phenotypic characteristics |
| Q37595435 | Candida antifungal drug resistance in sub-Saharan African populations: A systematic review |
| Q81978637 | Candida bloodstream infections in hemodialysis recipients |
| Q27012454 | Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later |
| Q38174838 | Candida identification: a journey from conventional to molecular methods in medical mycology |
| Q37942655 | Candida infections in non-neutropenic children after the neonatal period |
| Q45037784 | Candida kefyr, an uncommon but emerging fungal pathogen: report of two cases |
| Q34852747 | Candida parapsilosis, an emerging fungal pathogen |
| Q61797903 | Candida sp. Infections in Patients with Diabetes Mellitus |
| Q33241991 | Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links |
| Q42375493 | Candidaemia in a tertiary hospital in Nigeria |
| Q50763957 | Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. |
| Q46971625 | Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome |
| Q44768623 | Candidemia by species of the Candida parapsilosis complex in children's hospital: prevalence, biofilm production and antifungal susceptibility |
| Q34719299 | Candidemia in Norway (1991 to 2003): results from a nationwide study |
| Q80382945 | Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study |
| Q35028914 | Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients |
| Q36904887 | Candidemia in the in-patient setting: treatment options and economics |
| Q37443115 | Candidemia on presentation to the hospital: development and validation of a risk score |
| Q37699331 | Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs |
| Q36911813 | Candidiasis--do we need to fight or to tolerate the Candida fungus? |
| Q40404311 | Caspofungin activity against clinical isolates of fluconazole-resistant Candida |
| Q97597583 | Caspofungin suppresses zymosan-induced cytokine and chemokine release in THP-1 cells: Possible involvement of the spleen tyrosine kinase pathway |
| Q42593463 | Catalase activity of different Candida species after exposition to specific antiserum |
| Q34528210 | Catheter-related Candida bloodstream infection in intensive care unit patients: a subgroup analysis of the China-SCAN study |
| Q57497193 | Catheter-related candidemia and identification of causative species in patients with cardiovascular disorder |
| Q24195090 | Central venous catheter (CVC) removal for adult patients with candidaemia |
| Q26471135 | Central venous catheter (CVC) removal for patients of all ages with candidaemia |
| Q41711370 | Cervical Bone Graft Candida albicans Osteomyelitis: Management Strategies for an Uncommon Infection |
| Q36423773 | Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. |
| Q31054881 | Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study |
| Q40129265 | Chemical inhibitors of Candida albicans hyphal morphogenesis target endocytosis |
| Q37925912 | Chromatin-mediated Candida albicans virulence. |
| Q52577946 | Cleavage of E-cadherin: a mechanism for disruption of the intestinal epithelial barrier by Candida albicans. |
| Q34505582 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
| Q49100750 | Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections |
| Q35558411 | Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections |
| Q45052854 | Clinical and tree hollow populations of human pathogenic yeast in Hamilton, Ontario, Canada are different |
| Q37624696 | Clinical aspects of invasive candidiasis in critically ill patients |
| Q33807195 | Clinical characteristics and risk factors for nosocomial candidemia in medical intensive care units: experience in a single hospital in Korea for 6.6 years |
| Q42751895 | Clinical experience of anidulafungin for the treatment of patients with documented candidemia. |
| Q34936576 | Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. |
| Q35881281 | Clinical significance of the isolation of Candida species from hospitalized patients |
| Q46642455 | Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles. |
| Q36011378 | Combination treatment of invasive fungal infections |
| Q38823930 | Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations |
| Q40525731 | Comparison of BACTEC™ blood culture media for the detection of fungemia. |
| Q35915352 | Comparison of E,E-Farnesol Secretion and the Clinical Characteristics of Candida albicans Bloodstream Isolates from Different Multilocus Sequence Typing Clades. |
| Q28273738 | Comparison of echinocandin antifungals |
| Q59308857 | Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation |
| Q33704835 | Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. |
| Q34153658 | Comprehensive annotation of the transcriptome of the human fungal pathogen Candida albicans using RNA-seq |
| Q42129565 | Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform |
| Q89578301 | Contributions of the Biofilm Matrix to Candida Pathogenesis |
| Q27313251 | Control and manipulation of pathogens with an optical trap for live cell imaging of intercellular interactions |
| Q34218399 | Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain. |
| Q27670663 | Crystal Structures of Candida albicans Dihydrofolate Reductase Bound to Propargyl-Linked Antifolates Reveal the Flexibility of Active Site Loop Residues Critical for Ligand Potency and Selectivity |
| Q55347081 | Current Trends and Potential Applications of Microbial Interactions for Human Welfare. |
| Q37759256 | Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients |
| Q38531765 | Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis |
| Q46427960 | DS6: anticandidal, antibiofilm peptide against Candida tropicalis and exhibit synergy with commercial drug. |
| Q33224259 | Decoding serological response to Candida cell wall immunome into novel diagnostic, prognostic, and therapeutic candidates for systemic candidiasis by proteomic and bioinformatic analyses |
| Q37871069 | Design and use of Candida scores at the intensive care unit |
| Q82982919 | Detection of Candida albicans by mass spectrometric fingerprinting |
| Q28268148 | Determination of mRNA half-lives in Candida albicans using thiolutin as a transcription inhibitor |
| Q28477874 | Development of a high-throughput Candida albicans biofilm chip |
| Q37159565 | Developments in the epidemiolgy of invasive fungal infections - implications for the empiric and targeted antifungal therapy |
| Q36623050 | Developments in the treatment of candidiasis: more choices and new challenges |
| Q37889382 | Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy |
| Q38079194 | Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B. |
| Q40492126 | Diagnosis of candidemia by polymerase chain reaction and blood culture: prospective study in a high-risk population and identification of variables associated with development of candidemia |
| Q35574038 | Diagnosis of invasive candidiasis in the ICU. |
| Q35192301 | Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia |
| Q49609584 | Disease-based antimicrobial stewardship: a review of active and passive approaches to patient management |
| Q57168316 | Dispersed Cells Are Developmentally Distinct from Biofilm and Planktonic Cells |
| Q34596791 | Disruption of the transcriptional regulator Cas5 results in enhanced killing of Candida albicans by Fluconazole |
| Q35065859 | Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin |
| Q36776469 | Distinct and redundant roles of the two MYST histone acetyltransferases Esa1 and Sas2 in cell growth and morphogenesis of Candida albicans |
| Q35065740 | Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis |
| Q42930341 | Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. |
| Q35092764 | Drug susceptibility of matrix-encapsulated Candida albicans nano-biofilms |
| Q35871970 | Dysregulation of ion homeostasis by antifungal agents |
| Q36155799 | Ebselen exerts antifungal activity by regulating glutathione (GSH) and reactive oxygen species (ROS) production in fungal cells |
| Q28264860 | Echinocandins in the management of invasive fungal infections, Part 2 |
| Q41066834 | Echinocandins: A ray of hope in antifungal drug therapy |
| Q40004501 | Ecological structuring of yeasts associated with trees around Hamilton, Ontario, Canada |
| Q33559164 | Effect of antifungal therapy timing on mortality in cancer patients with candidemia |
| Q90337415 | Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study |
| Q42112304 | Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis |
| Q35025431 | Effect of statin use on outcomes of adults with candidemia |
| Q24537282 | Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. |
| Q43993301 | Effects of tigecycline and daptomycin on murine gut colonization by Candida albicans |
| Q35515892 | Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs |
| Q44737751 | Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease |
| Q37116545 | Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis |
| Q46772887 | Efficacy of micafungin for the treatment of candidemia |
| Q51168822 | Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species. |
| Q37283450 | Emergence of non-albicans Candida species in neonatal candidemia |
| Q36066009 | Emerging azole antifungals |
| Q26828993 | Emerging drugs and vaccines for candidemia |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q41840631 | Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little? |
| Q24303620 | Endogenous thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasis |
| Q43251110 | Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps |
| Q37576521 | Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital |
| Q40352038 | Epidemiological investigation of Candida species causing bloodstream infection in paediatric small bowel transplant recipients |
| Q33851338 | Epidemiology and antifungal susceptibility of Candida species in a tertiary care hospital, Kolkata, India |
| Q41726019 | Epidemiology and prognostic factors of candidemia in elderly patients |
| Q92772855 | Epidemiology and prognostic factors of nosocomial candidemia in Northeast Brazil: A six-year retrospective study |
| Q27024911 | Epidemiology and risk factors for invasive candidiasis |
| Q37524695 | Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002-20121 |
| Q40757551 | Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010. |
| Q89689856 | Epidemiology of candidemia and impact of infectious disease consultation on survival and care |
| Q35073043 | Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers |
| Q29616758 | Epidemiology of invasive candidiasis: a persistent public health problem |
| Q55292648 | Epidemiology, practice patterns, and prognostic factors for candidemia; and characteristics of fourteen patients with breakthrough Candida bloodstream infections: a single tertiary hospital experience in Japan. |
| Q90272421 | Epidemiology, risk factors and outcomes of Candida albicans vs. non-albicans candidaemia in adult patients in Northeast China |
| Q34148751 | Escherichia coli and TNF-alpha modulate macrophage phagocytosis of Candida glabrata |
| Q35636971 | Evaluation of "Candida score" in critically ill patients: a prospective, multicenter, observational, cohort study |
| Q37158073 | Evaluation of APR1 Gene Expression in Candida albicans Strains Isolated From Patients With Multiple Sclerosis |
| Q42590523 | Evaluation of a novel enzyme-linked immunosorbent assay to detect immunoglobulin G antibody to enolase for serodiagnosis of invasive candidiasis |
| Q35100177 | Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial |
| Q37565880 | Evaluation of treatment of invasive fungal infections |
| Q30994297 | Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance |
| Q33788125 | Expression of genes encoding innate host defense molecules in normal human monocytes in response to Candida albicans |
| Q33877204 | Expression, crystallization and preliminary X-ray data analysis of NT-Als9-2, a fungal adhesin from Candida albicans. |
| Q92075113 | Extensive ERG11 mutations associated with fluconazole-resistant Candida albicans isolated from HIV-infected patients |
| Q43219915 | Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. |
| Q83339404 | Farnesol restores wild-type colony morphology to 96% of Candida albicans colony morphology variants recovered following treatment with mutagens |
| Q27324379 | Flow Cytometry-Based Method To Detect Persisters in Candida albicans |
| Q37335827 | Fluconazole assists berberine to kill fluconazole-resistant Candida albicans |
| Q34490092 | Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? |
| Q83517792 | Fructose-1,6-bisphosphate reduces the mortality in Candida albicans bloodstream infection and prevents the septic-induced platelet decrease |
| Q33896940 | Fungal infections in transplant and oncology patients |
| Q46434501 | Fungal sepsis--therapeutical strategy |
| Q30808061 | Fungemia in a Spanish hospital: the role of Candida parapsilosis over a 15-year period |
| Q39413843 | Fungicidal photodynamic effect of a twofold positively charged porphyrin against Candida albicans planktonic cells and biofilms |
| Q33313469 | Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans |
| Q21999063 | Genetic and phenotypic intra-species variation in Candida albicans |
| Q33886289 | Genetic control of susceptibility to infection with Candida albicans in mice |
| Q35140108 | Genetic diversity among Korean Candida albicans bloodstream isolates: assessment by multilocus sequence typing and restriction endonuclease analysis of genomic DNA by use of BssHII. |
| Q90068142 | Global Transcriptomic Analysis of the Candida albicans Response to Treatment with a Novel Inhibitor of Filamentation |
| Q35059329 | Glycosylation status of the C. albicans cell wall affects the efficiency of neutrophil phagocytosis and killing but not cytokine signaling. |
| Q42178504 | Growth Inhibition and Membrane Permeabilization of Candida lusitaniae Using Varied Pulse Shape Electroporation |
| Q35119312 | High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation |
| Q35917505 | High-dose ascorbate with low-dose amphotericin B attenuates severity of disease in a model of the reappearance of candidemia during sepsis in the mouse |
| Q34729487 | High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors |
| Q37544689 | Histatin 5-spermidine conjugates have enhanced fungicidal activity and efficacy as a topical therapeutic for oral candidiasis. |
| Q33667782 | Histone acetyltransferase Rtt109 is required for Candida albicans pathogenesis. |
| Q37734169 | Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil |
| Q38179499 | Hsp90-dependent regulatory circuitry controlling temperature-dependent fungal development and virulence. |
| Q38015881 | Human genetic susceptibility to Candida infections. |
| Q89986135 | Human inborn errors of immunity underlying superficial or invasive candidiasis |
| Q46436789 | Hyperspectral fluorescence microscopy detects autofluorescent factors that can be exploited as a diagnostic method for Candida species differentiation |
| Q36648751 | Identification and Characterization of Wor4, a New Transcriptional Regulator of White-Opaque Switching |
| Q24628877 | Identification and characterization of a previously undescribed family of sequence-specific DNA-binding domains |
| Q35690934 | Identification of Candida Species Using MP65 Gene and Evaluation of the Candida albicans MP65 Gene Expression in BALB/C Mice |
| Q28550999 | Identification of New Antifungal Compounds Targeting Thioredoxin Reductase of Paracoccidioides Genus |
| Q40703127 | Imbalanced Macrophage and Dendritic Cell Activations in Response to Candida albicans in a Murine Model of Diabetes Mellitus |
| Q38590007 | Immune defence against Candida fungal infections |
| Q43163022 | Immune recognition of Candida albicans beta-glucan by dectin-1. |
| Q38609177 | Immunoglobulin G responses to a panel of Candida albicans antigens as accurate and early markers for the presence of systemic candidiasis |
| Q36869799 | Immunosensing during colonization by Candida albicans: does it take a village to colonize the intestine? |
| Q89732485 | Impact of Obesity in Patients with Candida Bloodstream Infections: A Retrospective Cohort Study |
| Q49346938 | Impact of an antifungal stewardship intervention on optimization of candidemia management |
| Q46255825 | Impact of automatic infectious diseases consultation on the management of fungemia at a large academic medical center |
| Q64239047 | Impact of empirical treatment with antifungal agents on survival of patients with candidemia |
| Q92430011 | Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161 |
| Q40821063 | Impaired killing of Candida albicans by granulocytes mobilized for transfusion purposes: a role for granule components |
| Q35689372 | Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi |
| Q35960782 | In vivo biocompatibility and in vitro efficacy of antimicrobial gendine-coated central catheters |
| Q37420953 | Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program |
| Q39092143 | Incidence, characteristics and outcome of ICU-acquired candidemia in India |
| Q44418924 | Increase in Candida parapsilosis fungemia in critical care units: a 6-years study |
| Q35192242 | Increased mortality in young candidemia patients associated with presence of a Candida albicans general-purpose genotype |
| Q35375409 | Increased susceptibility to Candida infection following cecal ligation and puncture |
| Q39355412 | Induction of cyclooxygenase-2 gene by Candida albicans through EGFR, ERK, and p38 pathways in human urinary epithelium |
| Q36513475 | Influence of IgG Subclass on Human Antimannan Antibody-Mediated Resistance to Hematogenously Disseminated Candidiasis in Mice |
| Q38949513 | Inhibition of biofilm formation and lipase in Candida albicans by culture filtrate of Staphylococcus epidermidis in vitro |
| Q36257873 | Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study |
| Q37950850 | Insights into Candida tropicalis nosocomial infections and virulence factors. |
| Q30479433 | Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines |
| Q37190996 | Interaction of Candida albicans with an intestinal pathogen, Salmonella enterica serovar Typhimurium |
| Q35131761 | Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series |
| Q34647337 | Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing |
| Q41654518 | Invasive Candida infections in patients of a medical intensive care unit: attempt of improving diagnosis by quantifying the colonization |
| Q46266195 | Invasive Candidiasis in pediatric patients at King Fahad Medical City in Central Saudi Arabia. A 5-year retrospective study |
| Q38263282 | Invasive candidiasis and candidaemia in neonates and children: update on current guidelines |
| Q22305429 | Invasive candidiasis as a cause of sepsis in the critically ill patient |
| Q44590119 | Invasive candidiasis in non-neutropenic adults : Guideline-based management in the intensive care unit |
| Q46711915 | Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists |
| Q38614492 | Invasive candidiasis: future directions in non-culture based diagnosis |
| Q38110850 | Invasive candidiasis: update on current pharmacotherapy options and future perspectives |
| Q46683505 | Invasive fungal infections at The Norwegian Radium Hospital 1998-2003. |
| Q37643057 | Invasive fungal infections in the ICU. |
| Q36959462 | Investigation of an unrecognized large-scale outbreak of Candida parapsilosis sensu stricto fungaemia in a tertiary-care hospital in China |
| Q43453146 | Is double coverage of gram-negative organisms necessary? |
| Q50917195 | Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil. |
| Q37263435 | Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model |
| Q36140647 | Liposomal amphotericin B: clinical experience and perspectives |
| Q37612914 | Low Caspofungin Exposure in Patients in Intensive Care Units. |
| Q37196885 | Low-dose amphotericin B and murine dialyzable spleen extracts protect against systemic candida infection in mice. |
| Q59307819 | MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting |
| Q34920621 | Management bundles for candidaemia: the impact of compliance on clinical outcomes |
| Q37313058 | Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. |
| Q35904821 | Management of invasive candidiasis in critically ill patients |
| Q36891368 | Manipulation of Host Diet To Reduce Gastrointestinal Colonization by the Opportunistic Pathogen Candida albicans |
| Q37720396 | Medically important bacterial-fungal interactions |
| Q47718243 | Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells. |
| Q34978993 | Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study |
| Q34006585 | Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis |
| Q80676337 | Microsatellite DNA identification and genotyping of Candida albicans from Lebanese clinical isolates |
| Q40292403 | Modelling the regulation of thermal adaptation in Candida albicans, a major fungal pathogen of humans |
| Q33320189 | Mucosal damage and neutropenia are required for Candida albicans dissemination |
| Q35066649 | Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. |
| Q30300387 | Multicenter evaluation of Candida QuickFISH BC for identification of Candida species directly from blood culture bottles |
| Q36749310 | Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting |
| Q35546961 | Multilocus Sequence Typing of Pathogenic Candida albicans Isolates Collected from a Teaching Hospital in Shanghai, China: A Molecular Epidemiology Study |
| Q34719660 | Multilocus sequence typing for analyses of clonality of Candida albicans strains in Taiwan |
| Q40938028 | Multilocus sequence typing is a reliable alternative method to DNA fingerprinting for discriminating among strains of Candida albicans |
| Q36506445 | Multilocus sequence typing of Candida tropicalis shows the presence of different clonal clusters and fluconazole susceptibility profiles in sequential isolates from candidemia patients in Sao Paulo, Brazil |
| Q64106838 | NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice |
| Q34489579 | Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain |
| Q36667530 | Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011 |
| Q41850594 | Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan |
| Q35177179 | New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study |
| Q35561959 | New signaling pathways govern the host response to C. albicans infection in various niches |
| Q36728707 | Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India |
| Q56935049 | Nosocomial Candidemia: An Ounce of Prevention Is Better Than a Pound of Cure |
| Q38589279 | Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis |
| Q28541447 | Nosocomial candidemia; risk factors and prognosis revisited; 11 years experience from a Norwegian secondary hospital |
| Q36825717 | Nosocomial fungal infections: epidemiology, diagnosis, and treatment |
| Q37763270 | Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy |
| Q35406737 | Novel strategies to fight Candida species infection. |
| Q38061190 | Occurrence, presentation and treatment of candidemia |
| Q37873399 | Opportunistic invasive fungal pathogen Macrophomina phaseolina prognosis from immunocompromised humans to potential mitogenic RBL with an exceptional and novel antitumor and cytotoxic effect. |
| Q33958720 | Oral health promotion interventions on oral yeast in hospitalised and medically compromised patients: a systematic review. |
| Q38215111 | Our 2014 approach to candidaemia |
| Q41683981 | Overexpression of the Transcriptional Regulator WOR1 Increases Susceptibility to Bile Salts and Adhesion to the Mouse Gut Mucosa in Candida albicans |
| Q34175500 | Overview of vertebrate animal models of fungal infection. |
| Q95840950 | Palmitic Acid Inhibits the Virulence Factors of Candida tropicalis: Biofilms, Cell Surface Hydrophobicity, Ergosterol Biosynthesis, and Enzymatic Activity |
| Q40045106 | Parasex Generates Phenotypic Diversity de Novo and Impacts Drug Resistance and Virulence in Candida albicans |
| Q24235328 | Patient isolation measures for infants with candida colonization or infection for preventing or reducing transmission of candida in neonatal units |
| Q24243803 | Patient isolation measures for infants with candida colonization or infection for preventing or reducing transmission of candida in neonatal units |
| Q37263189 | Patients at high risk of invasive fungal infections: when and how to treat |
| Q42263057 | Peripheral and total parenteral nutrition as the strongest risk factors for nosocomial candidemia in elderly patients: a matched case-control study |
| Q56884992 | Phage vaccines displaying YGKDVKDLFDYAQE epitope induce protection against systemic candidiasis in mouse model |
| Q34228214 | Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity |
| Q37229198 | Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of Candidemia |
| Q42577557 | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect |
| Q24563657 | Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia |
| Q57497191 | Phenotypic and genotypic characterization of species isolated from candideamia in Iran |
| Q35030065 | Photodynamic antimicrobial chemotherapy (PACT) inhibits biofilm formation by Candida albicans, increasing both ROS production and membrane permeability |
| Q36506518 | Physiologic expression of the Candida albicans pescadillo homolog is required for virulence in a murine model of hematogenously disseminated candidiasis |
| Q37052755 | Posaconazole in the management of refractory invasive fungal infections |
| Q36828159 | Posaconazole: a new broad-spectrum antifungal agent |
| Q40188974 | Posaconazole: a next-generation triazole antifungal |
| Q38257472 | Positive tip culture with Candida and negative blood culture: to treat or not to treat? A systematic review with meta-analysis |
| Q34509736 | Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole |
| Q37773252 | Potential of anti-Candida antibodies in immunoprophylaxis. |
| Q38009066 | Practical considerations on current guidelines for the management of non-neutropenic adult patients with candidaemia |
| Q37070069 | Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis |
| Q34485719 | Presence of Candida cell wall derived polysaccharides in the sera of intensive care unit patients: relation with candidaemia and Candida colonisation |
| Q40602135 | Prevalence and Fluconazole Susceptibility Profile of Candida spp. Clinical Isolates in a Brazilian Tertiary Hospital in Minas Gerais, Brazil |
| Q92156310 | Prevalence of Candida bloodstream isolates from patients in two hospitals in Vietnam |
| Q34057519 | Prevention of transmission of multidrug-resistant organisms during catheter exchange using antimicrobial catheters |
| Q34123634 | Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study |
| Q27653450 | Probing the Active Site ofCandida glabrataDihydrofolate Reductase with High Resolution Crystal Structures and the Synthesis of New Inhibitors |
| Q33369708 | Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans |
| Q35889819 | Prophylaxis and treatment of invasive candidiasis in the intensive care setting |
| Q53887873 | Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in adult surgical cancer patients. |
| Q39795440 | Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. |
| Q84660604 | Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-β-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease |
| Q43847211 | Protective immune responses against systemic candidiasis mediated by phage-displayed specific epitope of Candida albicans heat shock protein 90 in C57BL/6J mice |
| Q37734765 | Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy |
| Q36999660 | Rapid Detection of Candida albicans by Polymerase Spiral Reaction Assay in Clinical Blood Samples |
| Q51064987 | Rapid differentiation of Candida albicans from non-albicans species by germ tube test directly from BacTAlert blood culture bottles. |
| Q33527403 | Rapid species diagnosis for invasive candidiasis using mass spectrometry |
| Q35912243 | Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. |
| Q27472851 | Real-time PCR in clinical microbiology: applications for routine laboratory testing |
| Q35917383 | Recent advances in antifungal pharmacotherapy for invasive fungal infections |
| Q42727068 | Recognition and blocking of innate immunity cells by Candida albicans chitin |
| Q54216859 | Reduction in the percentage of clusters of Candida albicans and Candida parapsilosis causing candidemia in a general hospital in Madrid, Spain. |
| Q49956875 | Regulation of C-Type Lectin Receptor-Mediated Antifungal Immunity |
| Q64089378 | Regulation of Hyphal Morphogenesis by Endogenous Signals |
| Q46345548 | Relationship between susceptibility of Candida spp. isolates to amphotericin B and death or survival of patients with candidemia episodes |
| Q37783462 | Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review |
| Q90460596 | Repositionable Compounds with Antifungal Activity against Multidrug Resistant Candida auris Identified in the Medicines for Malaria Venture's Pathogen Box |
| Q35055832 | Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. |
| Q47107191 | Requirement for Ergosterol in Berberine Tolerance Underlies Synergism of Fluconazole and Berberine against Fluconazole-Resistant Candida albicans Isolates |
| Q42363614 | Residual Attributable Mortality, a New Concept for Understanding the Value of Antibiotics in Treating Life-Threatening Acute Infections |
| Q45892642 | Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients |
| Q34358699 | Retigeric acid B attenuates the virulence of Candida albicans via inhibiting adenylyl cyclase activity targeted by enhanced farnesol production |
| Q43529187 | Risk factors affecting in-hospital mortality in patients with nosocomial infections |
| Q90436045 | Risk factors for candidemia: a prospective matched case-control study |
| Q36228988 | Risk factors for early invasive fungal disease in critically ill patients |
| Q36073057 | Risk factors for invasive fungal disease in critically ill adult patients: a systematic review |
| Q90714231 | Risk factors predicting Candida infective endocarditis in patients with candidemia |
| Q43571511 | Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit |
| Q36313742 | Role of DNA mismatch repair and double-strand break repair in genome stability and antifungal drug resistance in Candida albicans |
| Q44211471 | Role of TLR1 and TLR6 in the host defense against disseminated candidiasis |
| Q33339288 | SSD1 is integral to host defense peptide resistance in Candida albicans |
| Q92238876 | Saccharomyces cerevisiae CNCM I-3856 as a New Therapeutic Agent Against Oropharyngeal Candidiasis |
| Q61441025 | Secreted aspartic proteases of Candida albicansactivate the NLRP3 inflammasome |
| Q34332272 | Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007 |
| Q35119972 | Septic shock due to candidemia: outcomes and predictors of shock development |
| Q35563279 | Sequence variations and protein expression levels of the two immune evasion proteins Gpm1 and Pra1 influence virulence of clinical Candida albicans isolates |
| Q33392309 | Shear stress modulates the thickness and architecture of Candida albicans biofilms in a phase-dependent manner |
| Q37636908 | Short-course therapy for bloodstream infections in immunocompetent adults |
| Q37007456 | Shuttle vectors for facile gap repair cloning and integration into a neutral locus in Candida albicans |
| Q43286148 | Simvastatin inhibits Candida albicans biofilm in vitro |
| Q43427231 | Six-year trend analysis of nosocomial candidemia and risk factors in two intensive care hospitals in Mato Grosso, midwest region of Brazil |
| Q35184456 | Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses |
| Q39665961 | Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study |
| Q35254046 | Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study |
| Q34374275 | Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery. |
| Q33595333 | Statins in candidemia: clinical outcomes from a matched cohort study |
| Q48163160 | Strategies to Reduce Mortality in Adult and Neonatal Candidemia in Developing Countries. |
| Q42707707 | Structural optimization of berberine as a synergist to restore antifungal activity of fluconazole against drug-resistant Candida albicans |
| Q37408350 | Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents |
| Q41832715 | Studies on the antifungal properties of N-thiolated beta-lactams |
| Q35625551 | Synergistic antifungal activity of berberine derivative B-7b and fluconazole |
| Q36245326 | Synthesis and Biological Evaluation of Novel 2-Aminonicotinamide Derivatives as Antifungal Agents |
| Q33719218 | Synthesis, characterization, and in vitro activity against Candida spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid) |
| Q42285405 | Syscan3, a kit for detection of anti-Candida antibodies for diagnosis of invasive candidiasis. |
| Q38864249 | Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy |
| Q35864807 | Systems biology of fungal infection. |
| Q84597136 | Ten-year study of species distribution and antifungal susceptibilities of Candida bloodstream isolates at a Brazilian tertiary hospital |
| Q37106755 | Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis |
| Q41661223 | The Candida albicans Inhibitory Activity of the Extract from Papaya (Carica papaya L.) Seed Relates to Mitochondria Dysfunction |
| Q47388204 | The Genomic Landscape of the Fungus-Specific SWI/SNF Complex Subunit, Snf6, in Candida albicans. |
| Q41200981 | The Monoterpene Carvacrol Generates Endoplasmic Reticulum Stress in the Pathogenic Fungus Candida albicans |
| Q37374119 | The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infections |
| Q26752567 | The Role of Autophagy-Related Proteins in Candida albicans Infections |
| Q43013559 | The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice |
| Q34601755 | The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis |
| Q46163150 | The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy |
| Q36289060 | The changing face of fungal infections in health care settings |
| Q27348287 | The conserved Candida albicans CA3427 gene product defines a new family of proteins exhibiting the generic periplasmic binding protein structural fold |
| Q51186546 | The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. |
| Q34335391 | The epidemiological profile of candidemia at an Indian trauma care center |
| Q51188122 | The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. |
| Q34586566 | The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study |
| Q38627825 | The essentiality of the fungus-specific Dam1 complex is correlated with a one-kinetochore-one-microtubule interaction present throughout the cell cycle, independent of the nature of a centromere |
| Q35248451 | The evolution of drug resistance in clinical isolates of Candida albicans |
| Q81083934 | The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis |
| Q37739596 | The global regulator Ncb2 escapes from the core promoter and impacts transcription in response to drug stress in Candida albicans. |
| Q35742928 | The impact of caspase-12 on susceptibility to candidemia |
| Q38423391 | The interplay between inflammasome activation and antifungal host defense |
| Q36516675 | The non-Geldanamycin Hsp90 inhibitors enhanced the antifungal activity of fluconazole |
| Q41966194 | The pH-regulated antigen 1 of Candida albicans binds the human complement inhibitor C4b-binding protein and mediates fungal complement evasion |
| Q33332302 | The parasexual cycle in Candida albicans provides an alternative pathway to meiosis for the formation of recombinant strains |
| Q43256196 | The photodynamic effect of methylene blue and toluidine blue on Candida albicans is dependent on medium conditions |
| Q36531751 | The role of Candida albicans AP-1 protein against host derived ROS in in vivo models of infection. |
| Q37349905 | The spectrum and aetiology of mycotic infections from a tertiary care hospital from Western part of India |
| Q33417649 | The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity |
| Q37800610 | The value of amphotericin B in the treatment of invasive fungal infections |
| Q36747533 | Time to blood culture positivity as a marker for catheter-related candidemia |
| Q44451231 | Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. |
| Q35765997 | Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. |
| Q35828187 | Toward more effective antifungal therapy: the prospects of combination therapy. |
| Q35216756 | Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazole-resistant Candida albicans strains through an Mcm1p binding site |
| Q33509505 | Transcriptional regulation of carbohydrate metabolism in the human pathogen Candida albicans |
| Q39979052 | Transcriptome profile of the vascular endothelial cell response to Candida albicans |
| Q38125931 | Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry. |
| Q35959489 | Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature |
| Q37443139 | Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. |
| Q38048853 | Treatment of candidiasis: insights from host genetics |
| Q36774262 | Treatment options in candidaemia |
| Q35664186 | Treatment principles for Candida and Cryptococcus |
| Q36898200 | Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study |
| Q34057076 | UPC2 is universally essential for azole antifungal resistance in Candida albicans |
| Q34058180 | UPC2A is required for high-level azole antifungal resistance in Candida glabrata |
| Q33690201 | Unexpected Transcripts in Tn7 orf19.2646 C. albicans Mutant Lead to Low Fungal Burden Phenotype In vivo |
| Q37892901 | Update on the optimal use of voriconazole for invasive fungal infections |
| Q44506237 | Use of antifungal agents in pediatric and adult high-risk areas |
| Q45945764 | Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study. |
| Q42136599 | Use of peptide nucleic acid-fluorescence in situ hybridization for definitive, rapid identification of five common Candida species |
| Q34315530 | Use of quantitative real-time PCR to study the kinetics of extracellular DNA released from Candida albicans, with implications for diagnosis of invasive Candidiasis |
| Q46978942 | Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia |
| Q38073195 | Using rapid diagnostic tests to optimize antimicrobial selection in antimicrobial stewardship programs |
| Q37029566 | Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia |
| Q33798458 | Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity |
| Q34000982 | Validation of a modified algorithm for the identification of yeast isolates using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS). |
| Q27338028 | Validation of the tetracycline regulatable gene expression system for the study of the pathogenesis of infectious disease |
| Q47749829 | What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. |
| Q33888842 | Wild-type Drosophila melanogaster as an alternative model system for investigating the pathogenicity of Candida albicans |
| Q90170919 | Yeast Infections after Esophagectomy: A Retrospective Analysis |
| Q90424700 | Yeast and Filaments Have Specialized, Independent Activities in a Zebrafish Model of Candida albicans Infection |
| Q81307340 | [Advances and limitations in the early diagnosis of invasive yeast infections] |
| Q82735043 | [Candida peritonitis] |
| Q46000235 | [Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients]. |
| Q45942591 | [Current treatment of candidemia. Role of anidulafungin]. |
| Q51181568 | [Epidemiology of invasive candidiasis in pediatric and adult populations]. |
| Q82653859 | [Prevention of invasive candidiasis in the critically ill non neutropenic patient] |
Search more.